Affiliation: Duke University Medical Center
- Aspirin exposure reveals novel genes associated with platelet function and cardiovascular eventsDeepak Voora
Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina Department of Medicine, Duke University, Durham, North Carolina Electronic address
J Am Coll Cardiol 62:1267-76. 2013..The aim of this study was to develop ribonucleic acid (RNA) profiles that could serve as novel biomarkers for the response to aspirin...
- Clinical application of cardiovascular pharmacogeneticsDeepak Voora
Duke Institute for Genome Science and Policy, Duke University, Durham, NC 27708, USA
J Am Coll Cardiol 60:9-20. 2012..Until the evidentiary gaps are filled, however, clinicians may choose to target therapeutics to individual patients whose genetic background indicates that they stand to benefit the most from pharmacogenetic testing...
- Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapyDeepak Voora
Institute for Genome Sciences and Policy, Duke University, 905 S Lasalle Dr, DUMC Box 3445, Durham, NC 27710, USA
J Thromb Thrombolysis 33:246-57. 2012..Despite suppression of COX-1 activity, NCDPF during aspirin therapy is predictably dynamic: those with heightened NCDPF continue to decline whereas those with low/normal NCDPF return to pre-aspirin levels over time...
- Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin useDeepak Voora
Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27710, USA
Am Heart J 162:166-72.e1. 2011....
- Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose responseDeepak Voora
Division of Cardiovascular Medicine, the Institute for Genome and Science Policy, and the Center for Human Genetics, Duke University, Durham, NC 27708, USA
Circ Cardiovasc Genet 1:100-6. 2008..There is interindividual variation in low-density lipoprotein cholesterol (LDLc) lowering by statins and limited study into the genetic associations of the dose dependant LDLc lowering by statins...
- The pharmacogenetics of antiplatelet agents: towards personalized therapy?Tariq Ahmad
Division of Cardiology, Duke University School of Medicine, 2400 Pratt Street, DUMC 3850, Durham, NC 27710, USA
Nat Rev Cardiol 8:560-71. 2011..Ongoing and future clinical trials might provide evidence to support a change in practice towards pharmacogenetic-based selection of antiplatelet therapy...
- SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterizationJosephine H Li
Duke Center for Applied Genomics and Precision Medicine, Duke University, 101 Science Drive, Durham, NC 27705, USA
Pharmacogenomics 16:449-58. 2015..SLCO1B1 variants are associated with intermediate outcomes that may increase risk of death/myocardial infarction (MI) in statin-treated patients...
- The SLCO1B1*5 genetic variant is associated with statin-induced side effectsDeepak Voora
Division of Cardiovascular Medicine, Duke University Medical Center, Durham, North Carolina 27708, USA
J Am Coll Cardiol 54:1609-16. 2009..We sought to identify single nucleotide polymorphisms associated with mild statin-induced side effects...
- Evaluation of the PharmGKB knowledge base as a resource for efficiently assessing the clinical validity and utility of pharmacogenetic assaysKensaku Kawamoto
Division of Clinical Informatics, Department of Community and Family Medicine, Duke University, Durham, NC, USA
AMIA Annu Symp Proc 2009:307-11. 2009..Thus, we conclude that PharmGKB can facilitate the systematic assessment of pharmacogenetic assays through the efficient identification of relevant peer-reviewed manuscripts...
- A hub for bench-to-bedside pharmacogenomic-based researchDeepak Voora
Institute for Genome Sciences and Policy, Center for Genomic Medicine, 101 Science Drive, Duke University, DUMC Box 3382, Durham, NC 27708, USA
Pharmacogenomics 12:1095-8. 2011..These new treatment paradigms can, potentially, ensure that the right dose of the right drug is prescribed to the right individual - an often stated goal of personalized medicine and pharmacogenomics...
- Preoperative CYP2D6 metabolism-dependent β-blocker use and mortality after coronary artery bypass grafting surgeryMiklos D Kertai
Division of Cardiothoracic Anesthesiology and Critical Care, Department of Anesthesiology, Duke University Medical Center, Durham, NC Electronic address
J Thorac Cardiovasc Surg 147:1368-1375.e3. 2014..The purpose of the present study was to assess the association between the preoperative use of BBs dependent on metabolism of the CYP2D6 isoenzyme with operative mortality after coronary artery bypass grafting surgery...
- Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablationThomas W Wallace
Duke Center for Atrial Fibrillation, Cardiac Electrophysiology Section of the Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
J Cardiovasc Electrophysiol 21:849-52. 2010..Catheter-directed atrial fibrillation (AF) ablation is contraindicated among patients with left atrial appendage (LAA) thrombus. The prevalence of LAA thrombus among fully anticoagulated patients undergoing AF ablation is unknown...